[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100060453":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":14,"centralContacts":7,"locations":19,"responsibleParty":7,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":63,"locationsCount":66},{"fullName":5,"class":6},"National Cancer Institute (NCI)","NIH",null,[9,12],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","goserelin acetate",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"raloxifene",[15],{"name":16,"affiliation":17,"role":18},"Anthony Howell, MD","The Christie NHS Foundation Trust","STUDY_CHAIR",[20],{"facility":21,"status":7,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":7},"Christie Hospital NHS Trust","Manchester","England","M20 4BX","United Kingdom","UK",{"type":28,"coordinates":29},"Point",[30,31],-2.23743,53.48095,{"lat":31,"lon":30},"100060453","raloxifene-and-goserelin-in-preventing-breast-cancer-in-women-with-a-family-history-of-breast-cancer-100060453",false,"NCT00031850","Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer","A Randomized Trial Of Raloxifene Plus Zoladex For Prevention Of Breast Cancer","DISEASE CHARACTERISTICS:\n\n* High genetic risk of developing breast cancer defined as one or more of the following:\n\n  * BRCA1 or BRCA2 germ-line mutation\n  * First-degree relative of known BRCA1 or BRCA2 mutation carrier\n  * Family with 4 or more relatives diagnosed with female or male breast cancer or ovarian cancer before the age of 60\n  * Two first-degree relatives diagnosed with breast cancer before the age of 40\n  * p53 germ-line mutation (classical Li-Fraumeni syndrome (LFS) only)\n  * First-degree relative of a carrier in a family with classical LFS\n  * Risk equivalent to any of the above confirmed by clinical geneticist\n* No evidence of breast cancer by mammography\n\n  * Suspicious lesions must be confirmed as non-malignant\n* No prior breast cancer\n* No prior prophylactic mastectomy\n* No plan for alternative prevention measures within the next 12 months\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 30 to 45\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Premenopausal (follicle-stimulating hormone in premenopausal range if not menstruating)\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* More than 10 years (excluding breast cancer risk)\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Adequate liver function\n\nRenal:\n\n* Adequate renal function\n\nCardiovascular:\n\n* No prior deep vein thrombosis\n\nPulmonary:\n\n* No prior pulmonary embolism\n\nOther:\n\n* Not pregnant\n* Fertile patients must use effective nonhormonal contraception\n* No psychological disorder that would preclude study compliance\n* No prior malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or cervical cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* Not specified\n\nEndocrine therapy:\n\n* No concurrent hormonal therapy (e.g., oral contraception or hormone replacement therapy)\n\nRadiotherapy:\n\n* Not specified\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* At least 30 days or 5 half-lives since prior investigational drugs\n* No concurrent anticoagulants","FEMALE","30 Years","45 Years",{"count":44,"type":45},150,"ESTIMATED","INTERVENTIONAL",[48],"NA","RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of raloxifene and goserelin may be effective in preventing breast cancer.\n\nPURPOSE: Randomized pilot study to study the effectiveness of combining raloxifene and goserelin in preventing breast cancer in women who have a family history of breast cancer.",[51],"Breast Cancer",[53],"breast cancer","COMPLETED","2013-06-25",{"date":57,"type":45},"2013-06-26",{"date":59,"type":7},"2000-03",{"date":61,"type":62},"2007-05","ACTUAL",{"name":64,"class":65},"Institute of Cancer Research, United Kingdom","OTHER",1]